Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) – Equities researchers at HC Wainwright issued their FY2029 earnings per share estimates for shares of Plus Therapeutics in a note issued to investors on Friday, March 28th. HC Wainwright analyst S. Lee expects that the company will post earnings per share of $0.95 for the year. HC Wainwright has a “Buy” rating and a $5.50 price target on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share.
PSTV has been the subject of a number of other research reports. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Plus Therapeutics in a research report on Friday, March 28th. Ascendiant Capital Markets decreased their target price on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a report on Monday, December 9th.
Plus Therapeutics Trading Up 7.4 %
PSTV stock opened at $1.02 on Monday. The firm’s 50-day moving average price is $1.10 and its two-hundred day moving average price is $1.23. The stock has a market capitalization of $6.01 million, a price-to-earnings ratio of -0.40 and a beta of 0.73. Plus Therapeutics has a 12-month low of $0.24 and a 12-month high of $2.67.
Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The firm had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.19 million.
About Plus Therapeutics
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
See Also
- Five stocks we like better than Plus Therapeutics
- How to Most Effectively Use the MarketBeat Earnings Screener
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- What is the Dogs of the Dow Strategy? Overview and Examples
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
